oseltamivir acid Search Results


95
MedChemExpress nais oseltamivir carboxylate oseltamivir
a NAI susceptibility of A/Denmark/524/2009 (H1N1)pdm09 NA-H274 (N2 numbering) wild-type reference virus. b NAI susceptibility of A/Denmark/528/2009 (H1N1)pdm09 NA-H274Y <t>oseltamivir/peramivir-resistant</t> reference virus. c NAI susceptibility of A/bottlenose dolphin/Florida/UFTt2203/2022 (Dolphin/FL) virus. Classifications follow WHO guidance for NAI susceptibility evaluation.
Nais Oseltamivir Carboxylate Oseltamivir, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pmc11026403-223-4-11
Average 95 stars, based on 1 article reviews
nais oseltamivir carboxylate oseltamivir - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
TargetMol oseltamivir carboxylate osv
Screening of anti-influenza A virus (A) Schematic of antiviral screening by HA assay. MDCK cells were infected with H1N1 or mock-infected at an MOI of 0.001 in the presence of inhibitors from compound libraries at 37°C for 48 h, after which the cell supernatant was collected to test the viral titer via HA assay. <t>Oseltamivir</t> and DMSO were added to the cells as positive controls and negative controls, respectively. (B) The results of antiviral inhibitor screening. A total of 5545 compounds were tested in primary and secondary screens via HA assay and cytopathic effect assay, and 2 compounds that have not been reported for further studies on the basis of their potency were selected. (C) Chemical structures of zafirlukast and nanchangmycin. (D) Cytotoxicity of zafirlukast and nanchangmycin. Zafirlukast and nanchangmycin at the indicated concentrations in DMSO (0.1 μM‒1000 μM) were added to the MDCK cells. Cell viability was determined by CCK-8 assay. (E) Antiviral activity of zafirlukast and nanchangmycin at different concentrations without cytotoxicity. The experiments were performed in triplicate. The mean value is shown with the standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001.
Oseltamivir Carboxylate Osv, supplied by TargetMol, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pmc12616723-41-0-15
Average 90 stars, based on 1 article reviews
oseltamivir carboxylate osv - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

91
Santa Cruz Biotechnology oseltamivir carboxylate
Screening of anti-influenza A virus (A) Schematic of antiviral screening by HA assay. MDCK cells were infected with H1N1 or mock-infected at an MOI of 0.001 in the presence of inhibitors from compound libraries at 37°C for 48 h, after which the cell supernatant was collected to test the viral titer via HA assay. <t>Oseltamivir</t> and DMSO were added to the cells as positive controls and negative controls, respectively. (B) The results of antiviral inhibitor screening. A total of 5545 compounds were tested in primary and secondary screens via HA assay and cytopathic effect assay, and 2 compounds that have not been reported for further studies on the basis of their potency were selected. (C) Chemical structures of zafirlukast and nanchangmycin. (D) Cytotoxicity of zafirlukast and nanchangmycin. Zafirlukast and nanchangmycin at the indicated concentrations in DMSO (0.1 μM‒1000 μM) were added to the MDCK cells. Cell viability was determined by CCK-8 assay. (E) Antiviral activity of zafirlukast and nanchangmycin at different concentrations without cytotoxicity. The experiments were performed in triplicate. The mean value is shown with the standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001.
Oseltamivir Carboxylate, supplied by Santa Cruz Biotechnology, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+Acid/10__1128_slash_msphere__00423___20-171-13-17
Average 91 stars, based on 1 article reviews
oseltamivir carboxylate - by Bioz Stars, 2026-11
91/100 stars
  Buy from Supplier

93
Toronto Research Chemicals oseltamivir acid
(A) Plaque reduction assay. MDCK cells in 6-well plates were infected with the WT or 39.29-resistant A/Perth/16/2009 viruses at 100 pfu/well for 1 hour. After removal of the virus inoculum, cells were overlaid with varying concentrations of <t>oseltamivir</t> acid in agarose. The numbers of plaques were counted for each virus and normalized to the number at the lowest oseltamivir acid concentration. The assay was done in triplicate with data presented as Mean +/- SEM. (B) Neuraminidase (NA) activity assay. Serial dilutions of the WT and 39.29-resistant viruses were incubated with a fluorescent NA substrate. NA activities as a function of the fluorescence intensities in relative fluorescence unit (RFU) were plotted on the y-axis versus the log10 virus dilutions on the x-axis. The assay was done in duplicate with data presented as Mean +/- SEM. (C) Virus dilutions with equal NA activities were incubated with varying concentrations of oseltamivir acid, followed by NA activity determination with the fluorescent NA substrate. The NA activities of each virus were normalized to the value at the lowest oseltamivir acid concentration. The assay was done in duplicate with data presented as Mean +/- SEM.
Oseltamivir Acid, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pmc04924800-366-13-15
Average 93 stars, based on 1 article reviews
oseltamivir acid - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

86
Toronto Research Chemicals oseltamivir d 3 phosphate
(A) Plaque reduction assay. MDCK cells in 6-well plates were infected with the WT or 39.29-resistant A/Perth/16/2009 viruses at 100 pfu/well for 1 hour. After removal of the virus inoculum, cells were overlaid with varying concentrations of <t>oseltamivir</t> acid in agarose. The numbers of plaques were counted for each virus and normalized to the number at the lowest oseltamivir acid concentration. The assay was done in triplicate with data presented as Mean +/- SEM. (B) Neuraminidase (NA) activity assay. Serial dilutions of the WT and 39.29-resistant viruses were incubated with a fluorescent NA substrate. NA activities as a function of the fluorescence intensities in relative fluorescence unit (RFU) were plotted on the y-axis versus the log10 virus dilutions on the x-axis. The assay was done in duplicate with data presented as Mean +/- SEM. (C) Virus dilutions with equal NA activities were incubated with varying concentrations of oseltamivir acid, followed by NA activity determination with the fluorescent NA substrate. The NA activities of each virus were normalized to the value at the lowest oseltamivir acid concentration. The assay was done in duplicate with data presented as Mean +/- SEM.
Oseltamivir D 3 Phosphate, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir-d3+Phosphate/pmc03262966-71-31-51
Average 86 stars, based on 1 article reviews
oseltamivir d 3 phosphate - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
Biosynth Carbosynth oseltamivir acid
Immunocompromised patients infected with the dual H275Y mutant influenza A(H1N1)pdm09 viruses.
Oseltamivir Acid, supplied by Biosynth Carbosynth, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pmc07559125-33-0-10
Average 90 stars, based on 1 article reviews
oseltamivir acid - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

93
Toronto Research Chemicals oseltamivir carboxylate
Immunocompromised patients infected with the dual H275Y mutant influenza A(H1N1)pdm09 viruses.
Oseltamivir Carboxylate, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+acid/pmc06476638-963-30-32
Average 93 stars, based on 1 article reviews
oseltamivir carboxylate - by Bioz Stars, 2026-11
93/100 stars
  Buy from Supplier

85
Toronto Research Chemicals oseltamivir carboxylic acid
Immunocompromised patients infected with the dual H275Y mutant influenza A(H1N1)pdm09 viruses.
Oseltamivir Carboxylic Acid, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 85/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+Acid/pmc03195024-114-12-18
Average 85 stars, based on 1 article reviews
oseltamivir carboxylic acid - by Bioz Stars, 2026-11
85/100 stars
  Buy from Supplier

95
Toronto Research Chemicals oseltamivir free acid
Sialic acid (α configuration), <t>oseltamivir</t> 1, zanamivir 2, peramivir 3 and the bicyclo[3.1.0]hexane scaffold 4.
Oseltamivir Free Acid, supplied by Toronto Research Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/Oseltamivir+Acid/pmc05831633-323-0-18
Average 95 stars, based on 1 article reviews
oseltamivir free acid - by Bioz Stars, 2026-11
95/100 stars
  Buy from Supplier

90
Molecular Dynamics Inc dynamics simulations of the structures of n9 neuraminidase with amino acid changes and oseltamivir
Sialic acid (α configuration), <t>oseltamivir</t> 1, zanamivir 2, peramivir 3 and the bicyclo[3.1.0]hexane scaffold 4.
Dynamics Simulations Of The Structures Of N9 Neuraminidase With Amino Acid Changes And Oseltamivir, supplied by Molecular Dynamics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/dynamics+simulations+of+the+structures+of+n9+neuraminidase+with+amino+acid+changes+and+oseltamivir/10__1128_slash_aac__00793___15-123-16-1
Average 90 stars, based on 1 article reviews
dynamics simulations of the structures of n9 neuraminidase with amino acid changes and oseltamivir - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Alsachim SAS oseltamivir acid
Sialic acid (α configuration), <t>oseltamivir</t> 1, zanamivir 2, peramivir 3 and the bicyclo[3.1.0]hexane scaffold 4.
Oseltamivir Acid, supplied by Alsachim SAS, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oseltamivir+acid/oseltamivir+acid/pmc04958211-28-2-4
Average 90 stars, based on 1 article reviews
oseltamivir acid - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


a NAI susceptibility of A/Denmark/524/2009 (H1N1)pdm09 NA-H274 (N2 numbering) wild-type reference virus. b NAI susceptibility of A/Denmark/528/2009 (H1N1)pdm09 NA-H274Y oseltamivir/peramivir-resistant reference virus. c NAI susceptibility of A/bottlenose dolphin/Florida/UFTt2203/2022 (Dolphin/FL) virus. Classifications follow WHO guidance for NAI susceptibility evaluation.

Journal: Communications Biology

Article Title: Highly pathogenic avian influenza A(H5N1) virus in a common bottlenose dolphin ( Tursiops truncatus ) in Florida

doi: 10.1038/s42003-024-06173-x

Figure Lengend Snippet: a NAI susceptibility of A/Denmark/524/2009 (H1N1)pdm09 NA-H274 (N2 numbering) wild-type reference virus. b NAI susceptibility of A/Denmark/528/2009 (H1N1)pdm09 NA-H274Y oseltamivir/peramivir-resistant reference virus. c NAI susceptibility of A/bottlenose dolphin/Florida/UFTt2203/2022 (Dolphin/FL) virus. Classifications follow WHO guidance for NAI susceptibility evaluation.

Article Snippet: Virus susceptibility to the NAIs oseltamivir carboxylate (oseltamivir), zanamivir, and peramivir (MedChem Express) was determined by fluorometric assay with the substrate 2′-(4-methylumberlliferyl)-α-D-N-acetylneuraminic acid (MUNANA) (Sigma) as described , with minor modifications.

Techniques: Virus

Screening of anti-influenza A virus (A) Schematic of antiviral screening by HA assay. MDCK cells were infected with H1N1 or mock-infected at an MOI of 0.001 in the presence of inhibitors from compound libraries at 37°C for 48 h, after which the cell supernatant was collected to test the viral titer via HA assay. Oseltamivir and DMSO were added to the cells as positive controls and negative controls, respectively. (B) The results of antiviral inhibitor screening. A total of 5545 compounds were tested in primary and secondary screens via HA assay and cytopathic effect assay, and 2 compounds that have not been reported for further studies on the basis of their potency were selected. (C) Chemical structures of zafirlukast and nanchangmycin. (D) Cytotoxicity of zafirlukast and nanchangmycin. Zafirlukast and nanchangmycin at the indicated concentrations in DMSO (0.1 μM‒1000 μM) were added to the MDCK cells. Cell viability was determined by CCK-8 assay. (E) Antiviral activity of zafirlukast and nanchangmycin at different concentrations without cytotoxicity. The experiments were performed in triplicate. The mean value is shown with the standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Acta Biochimica et Biophysica Sinica

Article Title: Nanchangmycin suppresses influenza A virus infection by blocking endosomal acidification

doi: 10.3724/abbs.2025102

Figure Lengend Snippet: Screening of anti-influenza A virus (A) Schematic of antiviral screening by HA assay. MDCK cells were infected with H1N1 or mock-infected at an MOI of 0.001 in the presence of inhibitors from compound libraries at 37°C for 48 h, after which the cell supernatant was collected to test the viral titer via HA assay. Oseltamivir and DMSO were added to the cells as positive controls and negative controls, respectively. (B) The results of antiviral inhibitor screening. A total of 5545 compounds were tested in primary and secondary screens via HA assay and cytopathic effect assay, and 2 compounds that have not been reported for further studies on the basis of their potency were selected. (C) Chemical structures of zafirlukast and nanchangmycin. (D) Cytotoxicity of zafirlukast and nanchangmycin. Zafirlukast and nanchangmycin at the indicated concentrations in DMSO (0.1 μM‒1000 μM) were added to the MDCK cells. Cell viability was determined by CCK-8 assay. (E) Antiviral activity of zafirlukast and nanchangmycin at different concentrations without cytotoxicity. The experiments were performed in triplicate. The mean value is shown with the standard deviation (SD). *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Oseltamivir carboxylate (OSV), oseltamivir phosphate (OSE), epigallocatechin gallate (EGCG) and ribavirin (RBV) were purchased from TargetMol.

Techniques: Virus, Hemagglutination Assay, Infection, CCK-8 Assay, Activity Assay, Standard Deviation

Effects of nanchangmycin on influenza A virus infection in vivo (A) Schematic representation of the antiviral study in a mouse model. The mice were intranasally infected with H1N1 or PBS. At 1 d.p.i., the mice were intragastrically administered with nanchangmycin (1 mg/kg/day) or oseltamivir (10 mg/kg/day). The same treatment was administered once per day for 7 days. The mice were monitored daily for survival for 21 days. Mice that lost more than 25% of their initial body weight were sacrificed. Weight loss (B) and mortality (C) were monitored for 21 days. Nanchangmycin and OSE reduced the lung index (D) and viral load (E) in the lungs of infected mice compared with those of the negative control. The data are shown as the mean ± SD (n = 8 mice in each group). *P < 0.05, **P < 0.01, ***P < 0.001.

Journal: Acta Biochimica et Biophysica Sinica

Article Title: Nanchangmycin suppresses influenza A virus infection by blocking endosomal acidification

doi: 10.3724/abbs.2025102

Figure Lengend Snippet: Effects of nanchangmycin on influenza A virus infection in vivo (A) Schematic representation of the antiviral study in a mouse model. The mice were intranasally infected with H1N1 or PBS. At 1 d.p.i., the mice were intragastrically administered with nanchangmycin (1 mg/kg/day) or oseltamivir (10 mg/kg/day). The same treatment was administered once per day for 7 days. The mice were monitored daily for survival for 21 days. Mice that lost more than 25% of their initial body weight were sacrificed. Weight loss (B) and mortality (C) were monitored for 21 days. Nanchangmycin and OSE reduced the lung index (D) and viral load (E) in the lungs of infected mice compared with those of the negative control. The data are shown as the mean ± SD (n = 8 mice in each group). *P < 0.05, **P < 0.01, ***P < 0.001.

Article Snippet: Oseltamivir carboxylate (OSV), oseltamivir phosphate (OSE), epigallocatechin gallate (EGCG) and ribavirin (RBV) were purchased from TargetMol.

Techniques: Virus, Infection, In Vivo, Negative Control

Effects of nanchangmycin on oseltamivir-resistant influenza virus infection in vitro MDCK cells were infected with oseltamivir-resistant influenza A virus at an MOI of 1 in the presence of nanchangmycin (0.1, 0.5 or 1 μM), bafilomycin (50 nM), oseltamivir (1 μM) and DMSO. Total RNA was extracted from cell lysates at 4, 12 or 24 h.i.p. The relative expression levels of viral mRNAs were assessed via RT-qPCR and normalized to that of β-actin mRNA. The data are presented as the mean ± SD.

Journal: Acta Biochimica et Biophysica Sinica

Article Title: Nanchangmycin suppresses influenza A virus infection by blocking endosomal acidification

doi: 10.3724/abbs.2025102

Figure Lengend Snippet: Effects of nanchangmycin on oseltamivir-resistant influenza virus infection in vitro MDCK cells were infected with oseltamivir-resistant influenza A virus at an MOI of 1 in the presence of nanchangmycin (0.1, 0.5 or 1 μM), bafilomycin (50 nM), oseltamivir (1 μM) and DMSO. Total RNA was extracted from cell lysates at 4, 12 or 24 h.i.p. The relative expression levels of viral mRNAs were assessed via RT-qPCR and normalized to that of β-actin mRNA. The data are presented as the mean ± SD.

Article Snippet: Oseltamivir carboxylate (OSV), oseltamivir phosphate (OSE), epigallocatechin gallate (EGCG) and ribavirin (RBV) were purchased from TargetMol.

Techniques: Virus, Infection, In Vitro, Expressing, Quantitative RT-PCR

(A) Plaque reduction assay. MDCK cells in 6-well plates were infected with the WT or 39.29-resistant A/Perth/16/2009 viruses at 100 pfu/well for 1 hour. After removal of the virus inoculum, cells were overlaid with varying concentrations of oseltamivir acid in agarose. The numbers of plaques were counted for each virus and normalized to the number at the lowest oseltamivir acid concentration. The assay was done in triplicate with data presented as Mean +/- SEM. (B) Neuraminidase (NA) activity assay. Serial dilutions of the WT and 39.29-resistant viruses were incubated with a fluorescent NA substrate. NA activities as a function of the fluorescence intensities in relative fluorescence unit (RFU) were plotted on the y-axis versus the log10 virus dilutions on the x-axis. The assay was done in duplicate with data presented as Mean +/- SEM. (C) Virus dilutions with equal NA activities were incubated with varying concentrations of oseltamivir acid, followed by NA activity determination with the fluorescent NA substrate. The NA activities of each virus were normalized to the value at the lowest oseltamivir acid concentration. The assay was done in duplicate with data presented as Mean +/- SEM.

Journal: PLoS Pathogens

Article Title: Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody

doi: 10.1371/journal.ppat.1005702

Figure Lengend Snippet: (A) Plaque reduction assay. MDCK cells in 6-well plates were infected with the WT or 39.29-resistant A/Perth/16/2009 viruses at 100 pfu/well for 1 hour. After removal of the virus inoculum, cells were overlaid with varying concentrations of oseltamivir acid in agarose. The numbers of plaques were counted for each virus and normalized to the number at the lowest oseltamivir acid concentration. The assay was done in triplicate with data presented as Mean +/- SEM. (B) Neuraminidase (NA) activity assay. Serial dilutions of the WT and 39.29-resistant viruses were incubated with a fluorescent NA substrate. NA activities as a function of the fluorescence intensities in relative fluorescence unit (RFU) were plotted on the y-axis versus the log10 virus dilutions on the x-axis. The assay was done in duplicate with data presented as Mean +/- SEM. (C) Virus dilutions with equal NA activities were incubated with varying concentrations of oseltamivir acid, followed by NA activity determination with the fluorescent NA substrate. The NA activities of each virus were normalized to the value at the lowest oseltamivir acid concentration. The assay was done in duplicate with data presented as Mean +/- SEM.

Article Snippet: After removal of the virus inoculum, cells were overlaid with varying concentrations of oseltamivir acid (Toronto Research Chemicals Cat# O700980) in Flu Media + 1% agarose and incubated at 37°C until plaques were visible.

Techniques: Infection, Virus, Concentration Assay, Activity Assay, Incubation, Fluorescence

Plaque reduction assay of viruses treated with  oseltamivir acid.

Journal: PLoS Pathogens

Article Title: Two Escape Mechanisms of Influenza A Virus to a Broadly Neutralizing Stalk-Binding Antibody

doi: 10.1371/journal.ppat.1005702

Figure Lengend Snippet: Plaque reduction assay of viruses treated with oseltamivir acid.

Article Snippet: After removal of the virus inoculum, cells were overlaid with varying concentrations of oseltamivir acid (Toronto Research Chemicals Cat# O700980) in Flu Media + 1% agarose and incubated at 37°C until plaques were visible.

Techniques:

Immunocompromised patients infected with the dual H275Y mutant influenza A(H1N1)pdm09 viruses.

Journal: Pathogens

Article Title: In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients

doi: 10.3390/pathogens9090725

Figure Lengend Snippet: Immunocompromised patients infected with the dual H275Y mutant influenza A(H1N1)pdm09 viruses.

Article Snippet: Oseltamivir acid, peramivir trihydrate, and zanamivir hydrate were purchased from Biosynth Carbosynth (Berkshire, UK).

Techniques: Infection, Mutagenesis

Antiviral susceptibilities of the dual H275Y mutant influenza A(H1N1)pdm09 viruses.

Journal: Pathogens

Article Title: In Vitro Characterization of Multidrug-Resistant Influenza A(H1N1)pdm09 Viruses Carrying a Dual Neuraminidase Mutation Isolated from Immunocompromised Patients

doi: 10.3390/pathogens9090725

Figure Lengend Snippet: Antiviral susceptibilities of the dual H275Y mutant influenza A(H1N1)pdm09 viruses.

Article Snippet: Oseltamivir acid, peramivir trihydrate, and zanamivir hydrate were purchased from Biosynth Carbosynth (Berkshire, UK).

Techniques: Mutagenesis

Sialic acid (α configuration), oseltamivir 1, zanamivir 2, peramivir 3 and the bicyclo[3.1.0]hexane scaffold 4.

Journal: PLoS ONE

Article Title: Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase

doi: 10.1371/journal.pone.0193623

Figure Lengend Snippet: Sialic acid (α configuration), oseltamivir 1, zanamivir 2, peramivir 3 and the bicyclo[3.1.0]hexane scaffold 4.

Article Snippet: Oseltamivir free acid and the substrate 2-(4-methylumbelliferyl) α- d -acetylneuraminic acid sodium salt hydrate (MUNANA) were purchased from Toronto Research Chemicals.

Techniques:

Control experiments with known NAIs. K i was determined for N1 wild-type andH274Y (both from virus A/Anhui/1/2005 H5N1) and N2 (A/Chicken/HongKong/G9/1997 H9N2).

Journal: PLoS ONE

Article Title: Design and synthesis of constrained bicyclic molecules as candidate inhibitors of influenza A neuraminidase

doi: 10.1371/journal.pone.0193623

Figure Lengend Snippet: Control experiments with known NAIs. K i was determined for N1 wild-type andH274Y (both from virus A/Anhui/1/2005 H5N1) and N2 (A/Chicken/HongKong/G9/1997 H9N2).

Article Snippet: Oseltamivir free acid and the substrate 2-(4-methylumbelliferyl) α- d -acetylneuraminic acid sodium salt hydrate (MUNANA) were purchased from Toronto Research Chemicals.

Techniques: Control, Virus